CHEK2 and breast cancer: Another study evaluating PV carriers in moderate-risk genes showed that using PRS, it is possible to reclassify more than 30% of CHEK2 and around 50% of ATM PV carriers that have a lower lifetime BC risk compared to the one expected only considering the carrier status [31].